{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T20:18:40Z","timestamp":1766866720256,"version":"3.48.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,27]]},"DOI":"10.7759\/cureus.100211","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T20:15:54Z","timestamp":1766866554000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Metachronous Prostate Adenocarcinoma and Chromophobe Renal Cell Carcinoma in a Nigerian Male Patient: Diagnostic and Therapeutic Challenges"],"prefix":"10.7759","author":[{"given":"Olurotimi J","family":"Badero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiana","family":"Ogunlana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adewumi","family":"Alabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Isibor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-025-01816-5","article-title":"Chromophobe renal cell carcinoma - a rare kidney cancer with limited therapy options: a narrative review","volume":"25","author":"Pashai Fakhri M","year":"2025","unstructured":"Pashai Fakhri M, Serth J, Br\u00e4sen JH, Ivanyi P, Kuczyk MA, Tezval H. Chromophobe renal cell carcinoma - a rare kidney cancer with limited therapy options: a narrative review. BMC Urol. 2025, 25:147. 10.1186\/s12894-025-01816-5","journal-title":"BMC Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4669","article-title":"Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?","volume":"27","author":"Stark JR","year":"2009","unstructured":"Stark JR, Perner S, Stampfer MJ, et al.. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?. J Clin Oncol. 2009, 27:3459-64. 10.1200\/JCO.2008.20.4669","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.05.002","article-title":"GEC\/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update","volume":"107","author":"Hoskin PJ","year":"2013","unstructured":"Hoskin PJ, Colombo A, Henry A, Niehoff P, Paulsen Hellebust T, Siebert FA, Kovacs G. GEC\/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol. 2013, 107:325-32. 10.1016\/j.radonc.2013.05.002","journal-title":"Radiother Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5114\/jcb.2014.45759","article-title":"High-dose-rate brachytherapy boost for prostate cancer: rationale and technique","volume":"6","author":"Morton GC","year":"2014","unstructured":"Morton GC. High-dose-rate brachytherapy boost for prostate cancer: rationale and technique. J Contemp Brachytherapy. 2014, 6:323-30. 10.5114\/jcb.2014.45759","journal-title":"J Contemp Brachytherapy"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01616","article-title":"Editorial: optimizing local therapy for high-risk prostate cancer: evidence and emerging options","volume":"10","author":"Zaorsky NG","year":"2020","unstructured":"Zaorsky NG, Spratt DE, Kishan AU, Culp SH, Showalter TN. Editorial: optimizing local therapy for high-risk prostate cancer: evidence and emerging options. Front Oncol. 2020, 10:1616. 10.3389\/fonc.2020.01616","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10690.x","article-title":"Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series","volume":"110","author":"Volpe A","year":"2012","unstructured":"Volpe A, Novara G, Antonelli A, et al.. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int. 2012, 110:76-83. 10.1111\/j.1464-410X.2011.10690.x","journal-title":"BJU Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4708154","article-title":"Combined immunohistochemistry for the \"Three 7\" markers (CK7, CD117, and Claudin-7) is useful in the diagnosis of chromophobe renal cell carcinoma and for the exclusion of mimics: diagnostic experience from a single institution","volume":"2019","author":"Zhou J","year":"2019","unstructured":"Zhou J, Yang X, Zhou L, Zhang P, Wang C. Combined immunohistochemistry for the \"Three 7\" markers (CK7, CD117, and Claudin-7) is useful in the diagnosis of chromophobe renal cell carcinoma and for the exclusion of mimics: diagnostic experience from a single institution. Dis Markers. 2019, 2019:4708154. 10.1155\/2019\/4708154","journal-title":"Dis Markers"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.14670\/HH-27.969","article-title":"Multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects","volume":"27","author":"Kuroda N","year":"2012","unstructured":"Kuroda N, Ohe C, Mikami S, et al.. Multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol. 2012, 27:969-74. 10.14670\/HH-27.969","journal-title":"Histol Histopathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318299f0fb","article-title":"The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters","volume":"37","author":"Delahunt B","year":"2013","unstructured":"Delahunt B, Cheville JC, Martignoni G, et al.. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013, 37:1490-504. 10.1097\/PAS.0b013e318299f0fb","journal-title":"Am J Surg Pathol"},{"key":"ref10","article-title":"The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours","year":"2022","unstructured":"Urinary and Male Genital Tumours. WHO Classification of Tumours, 5th Edition. IARC Publications, Lyon, France; 2022. https.\/\/publications.iarc.who.int\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/Urinary-And-Male-Genital-Tumou...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/415743-a-case-of-metachronous-prostate-adenocarcinoma-and-chromophobe-renal-cell-carcinoma-in-a-nigerian-male-patient-diagnostic-and-therapeutic-challenges","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T20:15:56Z","timestamp":1766866556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/415743-a-case-of-metachronous-prostate-adenocarcinoma-and-chromophobe-renal-cell-carcinoma-in-a-nigerian-male-patient-diagnostic-and-therapeutic-challenges"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.100211","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,27]]}}}